CMT2E Gene Therapy Project Successfully Completes Milestone 2
By: Kelsie Timbie, CMT Research Foundation A collaboration between Dr. Chris Lorson and Dr. Michael Garcia of the University of Missouri and funded by the CMT Research Foundation is producing promising results in an innovative new approach to treating CMT2E. CMT2E...Italian Research Group Completes CMT Research Foundation-Funded Project, Results Encourage Further Work in New Therapy for Adult and Elderly Patients with CMT1A/CMT1B
By: Kelsie Timbie, CMT Research Foundation The CMT Research Foundation is pleased to announce that Dr. Maurizio D’Antonio’s research team at San Raffaele Scientific Institute in Milan, Italy has completed their CMT Research Foundation-funded project...
2022 at CMTRF
Dear Friends of CMTRF, In preparing for another busy year at CMTRF, I took some time recently to look back at the accomplishments of 2022. I am immensely proud of what our team has achieved (summarized below) and I believe it underscores how CMTRF adds significant...CMT Research Foundation partners with Samsara Therapeutics to develop a novel class of drugs in CMT1A
By: Keith Fargo, PhD, Chief Science Officer The CMT Research Foundation is pleased to announce a new project with Samsara Therapeutics, a US/UK-based biotech company that is developing a novel class of drugs for CMT1A. CMT1A is caused by duplication of a stretch of...The CMT Research Foundation Invests Over $500,000 to Find a Single Gene Therapy for Possibly Every Form of CMT1B
By: Keith Fargo, PhD, Chief Science Officer CMT1B is one of the most common forms of CMT. In CMT1B, the part of the nervous system that is dysfunctional is the myelin sheath of the peripheral nerves. Created by cells called Schwann cells, myelin wraps around the parts...
Important Research News Announcements
- The phenotypic spectrum of pathogenic ATP1A1 variants expands: the novel p.P600R substitution causes demyelinating Charcot-Marie-Tooth disease February 4, 2023
- Diverse CMT2 neuropathies are linked to aberrant G3BP interactions in stress granules February 3, 2023
- Retraction: Charcot-Marie-Tooth Disease as a Risk Factor for Periprosthetic Fractures in Tibiotalocalcaneal Fusion With Intramedullary Nailing January 20, 2023
- INF2 mutations in patients with a broad phenotypic spectrum of Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis January 13, 2023
- Exercise induced myelin protein zero improvement in neuropathic pain rats January 11, 2023
- A meta-analysis on the prevalence of Charcot-Marie-Tooth disease and related inherited peripheral neuropathies January 11, 2023
- X-linked Charcot-Marie-Tooth disease after SARS-CoV-2 vaccination mimicked stroke-like episodes: A case report January 11, 2023
- Targeting the PMP22 Protein to Develop Leads Against Charcot-Marie-Tooth Disease December 31, 2022
- Actin-mediated regulation of organelle dynamics in Charcot-Marie-Tooth disease December 31, 2022
- Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model December 30, 2022